SXTP Valuation

60 Degrees Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.310

-0.03(-2.239%)1D

Overview
Forecast
Valuation
Earnings

SXTP Relative Valuation

SXTP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SXTP is overvalued; if below, it's undervalued.

Historical Valuation

60 Degrees Pharmaceuticals Inc (SXTP) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2.65 is considered Overvalued compared with the five-year average of -0.88. The fair price of 60 Degrees Pharmaceuticals Inc (SXTP) is between 0.58 to 1.09 according to relative valuation methord. Compared to the current price of 1.31 USD , 60 Degrees Pharmaceuticals Inc is Overvalued By 20.25%.

Relative Value

Fair Zone

0.58-1.09

Current Price：1.31

20.25%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-0.78

P/B

Median3y

-0.61

Median5y

-0.61

-144.42

FCF Yield

Median3y

-160.81

Median5y

-160.81

Competitors Valuation Multiple

The average P/S ratio for SXTP's competitors is 0.48, providing a benchmark for relative valuation. 60 Degrees Pharmaceuticals Inc Corp (SXTP) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 75.42%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SXTP.O

60 Degrees Pharmaceuticals Inc

Loss

Average P/S: 0.48

75.42%